Krenitsky Pharmaceuticals Home Page

Krenitsky Pharmaceuticals Inc. (KPI) is a privately held drug company in Chapel Hill, NC founded in 1995 after acquisition of Burroughs Wellcome by Glaxo Inc. The President and CEO of KPI, Thomas A. Krenitsky, was formerly the Vice President of Research at Burroughs Wellcome.


Who We Are:

What We Do:

Since its founding, KPI has been focused on the discovery and early development of drugs for treating diseases of the central nervous system.  The company has been successful in the discovery of two drugs with significant commercial potential.  KPI completed a comprehensive series of preclinical studies demonstrating the biological activity of these drugs, and both drugs were licensed out for clinical development.  Recently, the licensee incurred financial difficulties and was forced to discontinue the clinical development program.  All rights to both drugs reverted to KPI in 2013. KPI has relicensed TriRima to Cennerv Pharma and is presently seeking a new partner for further development and commercialization of KP544.

Drug Candidates for Development

    KP544: A small molecule substituted pyrimidine that has demonstrated neuroprotective activity in neurological and peripheral neuropathy applications.

    Stage of development: The drug is currently in Phase I.

    Therapeutic uses:

    • Neurodegenerative conditions such as Mild Cognitive Impairment, Alzheimer’s disease and Huntington’s disease.
    • Treatment of chemically induced (Taxol) peripheral neuropathy.

TriRima: A triple acting, selective and reversible inhibitor of monoamine oxidase-A (MAO-A).

Stage of development: The drug has completed Phase IIa.

Therapeutic use: Depression and related conditions such as anxiety and ADHD.

 
Home KP544

TriRima

 

Contact Us